Lasca (Dienogest, Ethinylestradiol)

Dienogest/Ethinylestradiol, the active ingredients in Lasca, are a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus and endometrial lining.

GNH USA supplies Lasca as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lasca, a combined oral contraceptive, is used within the hormonal contraceptive pathway to prevent pregnancy.

Prevention of pregnancy: provides effective birth control for women of childbearing age. Regulation of menstrual bleeding: helps achieve more predictable bleeding patterns in women using hormonal contraception.

Lasca may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Breast tenderness - Headache - Weight gain or fluid retention - Mood changes - Breakthrough or spotting bleeding

Serious or Rare Side Effects: - Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism) - Arterial thrombosis (stroke, myocardial infarction) - Hypertension or worsening of existing high blood pressure - Liver dysfunction or cholestasis - Severe allergic reactions (anaphylaxis, angioedema) - Visual disturbances or ocular migraines

Before prescribing Lasca, clinicians should evaluate individual risk factors and counsel patients on safe use. - Assess cardiovascular risk: review history of thromboembolism, hypertension, or smoking. - Avoid smoking: especially in women over 35 years of age. - Monitor blood pressure: contraceptives may increase systolic or diastolic pressure. - Consider liver function: hepatic impairment can alter hormone metabolism. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Lasca can interact with several medication classes, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin) may reduce contraceptive efficacy. - Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) may increase hormone levels and risk of side effects. - Concurrent use with other estrogen‑containing products (e.g., hormone replacement therapy) may raise thrombotic risk.

Moderate Interactions (Monitor Closely): - Rifampin and other potent antibiotics can lower effectiveness. - St. John’s wort and similar herbal supplements may decrease plasma concentrations. - Certain SSRIs may potentiate mood‑related side effects.